How Smarteeva Reads the MIT Report on 95% AI Project Failure - And Why MedTech Is Different
What the MIT Report Actually Says
The 95% failure refers specifically to custom enterprise AI projects that never make it from pilot to durable, P&L-relevant production. Generic chat tools see adoption but do not change workflows. The study identifies three core barriers: a learning gap where tools do not retain feedback or adapt to context, lack of integration into daily operations, and the finding that external partnerships outperform internal builds by a factor of two.
The authors also acknowledge their own methodological limits, making the 95% claim directional rather than universal. It is a procurement warning, not an AI obituary.
Why Consultant-Led and Internal AI Builds Fail in MedTech
Consultant-led projects often produce committee-ware. Internal IT and large system integrators can align stakeholders, but they rarely ship performant, AI-native software validated for regulated environments. Smarteeva’s deployments deliver live systems in as few as 12 weeks for the same companies that previously spent years on internal AI projects.
Several Smarteeva clients had previously invested large sums in internal NLP and classification tools that failed validation. Smarteeva’s vertical knowledge and purpose-built tools achieved 98% accuracy within the first production cycle.
98% classification accuracy in first production cycle
12 weeks from configuration to live, validated deployment
Why Vertical AI Products Win in Regulated Environments
AI-washed add-ons lose to native vertical products. Smarteeva’s success in replacing generative automation bots reflects a clear pattern: deep integration with quality systems and regulatory workflows drives adoption. Domain knowledge matters. Feedback loops trained on MedTech compliance data produce better outcomes than general-purpose models.
The MIT report’s finding that external partnerships outperform internal builds confirms what Smarteeva sees in every deployment. Companies that try to build their own AI for complaint classification, reportability, and regulatory coding end up maintaining expensive custom systems that cannot keep pace with regulatory changes. Vertical products absorb that complexity.
Where the Real ROI Lives
Keywords: AI ROI medical devices, back-office AI automation
AI gets pushed by management toward Sales and Marketing. That is fine. But from Smarteeva’s experience, most of the ROI comes from allowing the back office to operate more efficiently. Complaint intake, adverse event classification, regulatory reporting, and risk assessment are high-volume, rules-based processes where AI delivers measurable time and cost savings.
When PMS teams stop spending 80% of their time on data entry and start spending it on risk assessment and product improvement, the operational impact is immediate and visible.
70% faster complaint resolution on Smarteeva
8 min PSUR generation replacing hours of manual work
Closing
Do not generalize the 95% failure rate into AI pessimism. Read it as a procurement warning. Generic tools, big-bang consultant builds, and non-vertical systems fail. To get on the right side of the AI divide, partner with vertical product companies that embed into your regulated workflows, learn from your feedback, and deliver clear operational outcomes.
